**17. References**


Evaluating Lymphoma Risk in Inflammatory Bowel Disease 343

Beaugerie, L., Seksik, P. & Carrat, F. 2009b. Thiopurine therapy is associated with a three-

Beaugerie, L., Seksik, P., Nion-Larmurier, I., Gendre, J. P. & Cosnes, J. 2006. Predictors of

Beaugerie, L., Sokol, H. & Seksik, P. 2009c. Noncolorectal malignancies in inflammatory

Belhadj, K., Reyes, F., Farcet, J. P., Tilly, H., Bastard, C., Angonin, R., Deconinck, E.,

Bernstein, C. N. 2010. Epidemiologic clues to inflammatory bowel disease. *Curr Gastroenterol* 

Bernstein, C. N., Blanchard, J. F., Kliewer, E. & Wajda, A. 2001. Cancer risk in patients with inflammatory bowel disease: a population-based study. *Cancer,* 91, 854-62. Biancone, L., Orlando, A., Kohn, A., Colombo, E., Sostegni, R., Angelucci, E., Rizzello, F.,

Bo, J., Schroder, H., Kristinsson, J., Madsen, B., Szumlanski, C., Weinshilboum, R., Andersen,

Bourikas, L. A., Tzardi, M., Hatzidakis, A. & Koutroubakis, I. E. 2008. Small bowel

Bours, P. H., Wielders, J. P., Vermeijden, J. R. & Van De Wiel, A. 2010. Seasonal variation of

Brenner, D. J. & Hall, E. J. 2007. Computed tomography--an increasing source of radiation

Brenner, D. J., Doll, R., Goodhead, D. T., Hall, E. J., Land, C. E., Little, J. B., Lubin, J. H.,

assessing what we really know. *Proc Natl Acad Sci U S A,* 100, 13761-6.

lymphoma, and multiple myeloma. *JAMA,* 265, 1290-4.

systemic lupus erythematosus. *Dig Liver Dis,* 40, 144.

bowel disease: more than meets the eye. *Dig Dis,* 27, 375-81.

observational cohort study. *Lancet,* 374, 1617-25.

Crohn's disease. *Gastroenterology,* 130, 650-6.

of 21 patients. *Blood,* 102, 4261-9.

*Rep,* 12, 495-501.

study. *Gut,* 55, 228-33.

disease. *Osteoporos Int*.

exposure. *N Engl J Med,* 357, 2277-84.

*Colitis,* 3.

Hermine, O., Faivre, J. & Carrat, F. 2009a. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective

fold decrease in the incidence of advanced neoplaisa in IBD patients with longstanding extensive colitis: the CESAME prospective data. *Journal of Crohn's and* 

Charlotte, F., Leblond, V., Labouyrie, E., Lederlin, P., Emile, J. F., Delmas-Marsalet, B., Arnulf, B., Zafrani, E. S. & Gaulard, P. 2003. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series

Castiglione, F., Benazzato, L., Papi, C., Meucci, G., Riegler, G., Petruzziello, C., Mocciaro, F., Geremia, A., Calabrese, E., Cottone, M. & Pallone, F. 2006. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair

J. B. & Schmiegelow, K. 1999. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. *Cancer,* 86, 1080-6. Boice, J. D., Jr. 1992. Radiation and non-Hodgkin's lymphoma. *Cancer Res,* 52, 5489s-5491s. Boice, J. D., Jr., Morin, M. M., Glass, A. G., Friedman, G. D., Stovall, M., Hoover, R. N. &

Fraumeni, J. F., JR. 1991. Diagnostic x-ray procedures and risk of leukemia,

perforation due to non-Hodgkin-lymphoma in a patient with ulcerative colitis and

serum 25-hydroxyvitamin D levels in adult patients with inflammatory bowel

Preston, D. L., Preston, R. J., Puskin, J. S., Ron, E., Sachs, R. K., Samet, J. M., Setlow, R. B. & Zaider, M. 2003. Cancer risks attributable to low doses of ionizing radiation:


Ardizzone, S., Maconi, G., Colombo, E., Manzionna, G., Bollani, S. & Bianchi Porro, G. 2004.

Armstrong, B. K. & Kricker, A. 2007. Sun exposure and non-Hodgkin lymphoma. *Cancer* 

Armstrong, R. G., West, J. & Card, T. R. 2010. Risk of cancer in inflammatory bowel disease

Arseneau, K. O., Stukenborg, G. J., Connors, A. F., Jr. & Cominelli, F. 2001. The incidence of

Askling, J., Brandt, L., Lapidus, A., Karlen, P., Bjorkholm, M., Lofberg, R. & Ekbom, A. 2005.

Aydogan, A., Corapcioglu, F., Elemen, E. L., Oncel, S., Gurbuz, Y. & Tugay, M. 2010.

Bacon, P. A. & Salmon, M. 1987. Modes of action of second-line agents. *Scand J Rheumatol* 

Baecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., Catrina, A. I.,

Bargen, J. 1928. Chronic ulcerative colitis associated with malignant disease. *Arch Surg,* 17,

Barrett, J. C., Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R.,

Bartram, C. & Chrispin, A. R. 1973. Primary lymphosarcoma of the ileum and caecum.

Basic-Jukic, N., Radman, I., Roncevic, T. & Jakic-Razumovic, J. 2002. Hodgkin s disease with

Beaugerie, L., Brousse, N., Bouvier, A. M., Colombel, J. F., Lemann, M., Cosnes, J.,

nephrotic syndrome as a complication of ulcerative colitis: case report. *Croat Med J,*

Hebuterne, X., Cortot, A., Bouhnik, Y., Gendre, J. P., Simon, T., Maynadie, M.,

outcome. *Inflamm Bowel Dis,* 10, 91-6.

*Epidemiol Biomarkers Prev,* 16, 396-400.

of Crohn's disease. *Turk J Pediatr,* 52, 411-5.

rheumatoid arthritis. *Arthritis Rheum,* 54, 692-701.

Crohn's disease. *Nat Genet,* 40, 955-62.

*Pediatr Radiol,* 1, 28-33.

43, 573-5.

*Gastroenterol,* 105, 1604-9.

*Inflamm Bowel Dis,* 7, 106-12.

617-22.

561-576.

*Suppl,* 64, 17-24.

Perianal fistulae following infliximab treatment: clinical and endosonographic

treated with azathioprine: a UK population-based case-control study. *Am J* 

lymphoid and myeloid malignancies among hospitalized Crohn's disease patients.

Risk of haematopoietic cancer in patients with inflammatory bowel disease. *Gut,* 54,

Childhood non-Hodgkin's lymphoma arising as a complication early in the course

Rosenquist, R., Feltelius, N., Sundstrom, C. & Klareskog, L. 2006. Association of chronic inflammation, not its treatment, with increased lymphoma risk in

Silverberg, M. S., Taylor, K. D., Barmada, M. M., Bitton, A., Dassopoulos, T., Datta, L. W., Green, T., Griffiths, A. M., Kistner, E. O., Murtha, M. T., Regueiro, M. D., Rotter, J. I., Schumm, L. P., Steinhart, A. H., Targan, S. R., Xavier, R. J., Libioulle, C., Sandor, C., Lathrop, M., Belaiche, J., Dewit, O., Gut, I., Heath, S., Laukens, D., Mni, M., Rutgeerts, P., Van Gossum, A., Zelenika, D., Franchimont, D., Hugot, J. P., De Vos, M., Vermeire, S., Louis, E., Cardon, L. R., Anderson, C. A., Drummond, H., Nimmo, E., Ahmad, T., Prescott, N. J., Onnie, C. M., Fisher, S. A., Marchini, J., Ghori, J., Bumpstead, S., Gwilliam, R., Tremelling, M., Deloukas, P., Mansfield, J., Jewell, D., Satsangi, J., Mathew, C. G., Parkes, M., Georges, M. & Daly, M. J. 2008. Genome-wide association defines more than 30 distinct susceptibility loci for Hermine, O., Faivre, J. & Carrat, F. 2009a. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Lancet,* 374, 1617-25.


Evaluating Lymphoma Risk in Inflammatory Bowel Disease 345

Dayharsh, G. A., Loftus, E. V., Jr., Sandborn, W. J., Tremaine, W. J., Zinsmeister, A. R.,

Debenedet, A. T., Berg, C. L., Enfield, K. B., Woodford, R. L., Bennett, A. K. & Northup, P. G.

Deneau, M., Wallentine, J., Guthery, S., O'gorman, M., Bohnsack, J., Fluchel, M., Bezzant, J.

D'haens, G. R. 2009. Top-down therapy for Crohn's disease: rationale and evidence. *Acta* 

Diebold, D. 2001. World Health Organisation Classification of Malignant Lymphomas.

Disanti, W., Rajapakse, R. O., Korelitz, B. I., Panagopoulos, G. & Bratcher, J. 2006. Incidence

Doody, M. M., Lonstein, J. E., Stovall, M., Hacker, D. G., Luckyanov, N. & Land, C. E. 2000.

Ekbom, A., Helmick, C., Zack, M. & Adami, H. O. 1991. Extracolonic malignancies in

Ekstrom Smedby, K., Vajdic, C. M., Falster, M., Engels, E. A., Martinez-Maza, O., Turner, J.,

pooled analysis within the InterLymph Consortium. *Blood,* 111, 4029-38. Epstein, M. A., Achong, B. G. & Barr, Y. M. 1964. Virus Particles in Cultured Lymphoblasts

Falchook, G. S., Vega, F., Dang, N. H., Samaniego, F., Rodriguez, M. A., Champlin, R. E.,

Feagan, B. G., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H.,

Hosing, C., Verstovsek, S. & Pro, B. 2009. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. *Ann Oncol,* 20, 1080-5. Farrell, R. J., Ang, Y., Kileen, P., O'briain, D. S., Kelleher, D., Keeling, P. W. & Weir, D. G.

2000. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. *Gut,* 47,

Greenberg, G. R., Koval, J., Wong, C. J., Hopkins, M., Hanauer, S. B. & Mcdonald, J.

or 6-mercaptopurine. *Gastroenterology,* 122, 72-7.

lymphoma. *Nat Clin Pract Gastroenterol Hepatol,* 5, 49-53.

inflammatory bowel disease. *Pediatrics,* 126, e977-81.

Scoliosis Cohort Study. *Spine (Phila Pa 1976),* 25, 2052-63.

inflammatory bowel disease. *Cancer,* 67, 2015-9.

from Burkitt's Lymphoma. *Lancet,* 1, 702-3.

FDA. 2011. *FDA* [Online]. Available: http://www.fda.gov/.

514-9.

*BMJ,* 304, 1005-9.

*Clin Belg,* 64, 540-6.

*Experimental Oncology,* 23, 101-103.

*Gastroenterol Hepatol,* 4, 1025-9.

Nordic countries in relation to fallout from atmospheric nuclear weapons testing.

Witzig, T. E., Macon, W. R. & Burgart, L. J. 2002. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine

2008. A case of vanishing bile duct syndrome and IBD secondary to Hodgkin's

& Pohl, J. F. 2010. Natural killer cell lymphoma in a pediatric patient with

of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease. *Clin* 

Breast cancer mortality after diagnostic radiography: findings from the U.S.

Hjalgrim, H., Vineis, P., Seniori Costantini, A., Bracci, P. M., Holly, E. A., Willett, E., Spinelli, J. J., La Vecchia, C., Zheng, T., Becker, N., De Sanjose, S., Chiu, B. C., Dal Maso, L., Cocco, P., Maynadie, M., Foretova, L., Staines, A., Brennan, P., Davis, S., Severson, R., Cerhan, J. R., Breen, E. C., Birmann, B., Grulich, A. E. & Cozen, W. 2008. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a


Camera, L., Della Noce, M. & Cirillo, L. C. 1997. [Primary ileo-cecal lymphoma mimicking

Carbone, J., Gonzalez-Lara, V., Sarmiento, E., Chean, C., Perez, J. L., Marin, I., Rodriguez-

Chandesris, M. O., Malamut, G., Verkarre, V., Meresse, B., Macintyre, E., Delarue, R., Rubio,

Chang, E. T., Smedby, K. E., Hjalgrim, H., Porwit-Macdonald, A., Roos, G., Glimelius, B. &

Chiorean, M. V., Pokhrel, B., Adabala, J., Helper, D. J., Johnson, C. S. & Juliar, B. 2010.

Cho, J. H. 2008. The genetics and immunopathogenesis of inflammatory bowel disease. *Nat* 

Cohen, R. D. 2001. Efficacy and safety of repeated infliximab infusions for Crohn's disease:

Coleman, J. R. 1999. Cancer Survival Trends in England & Wales, 1971-1995 by deprivation

Colombel, J. F., Loftus, E. V., Jr., Tremaine, W. J., Egan, L. J., Harmsen, W. S., Schleck, C. D.,

Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz,

Connell, W. R., Kamm, M. A., Dickson, M., Balkwill, A. M., Ritchie, J. K. & Lennard-Jones, J.

Cosnes, J., Nion-Larmurier, I., Beaugerie, L., Afchain, P., Tiret, E. & Gendre, J. P. 2005.

Dal Maso, L. & Franceschi, S. 2006. Hepatitis C virus and risk of lymphoma and other

Darby, S. C., Olsen, J. H., Doll, R., Thakrar, B., Brown, P. D., Storm, H. H., Barlow, L.,

Zinsmeister, A. R. & Sandborn, W. J. 2004. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

D., Lichtiger, S., D'haens, G., Diamond, R. H., Broussard, D. L., Tang, K. L., Van Der Woude, C. J. & Rutgeerts, P. 2010. Infliximab, azathioprine, or combination therapy

E. 1994. Long-term neoplasia risk after azathioprine treatment in inflammatory

Impact of the increasing use of immunosuppressants in Crohn's disease on the

lymphoid neoplasms: a meta-analysis of epidemiologic studies. *Cancer Epidemiol* 

Langmark, F., Teppo, L. & Tulinius, H. 1992. Trends in childhood leukaemia in the

1-year clinical experience. *Inflamm Bowel Dis,* 7 Suppl 1, S17-22.

Molina, J. J., Gil, J. & Fernandez-Cruz, E. 2007. Humoral and cellular monitoring to predict the development of infection in Crohn's disease patients beginning

M. T., Suarez, F., Deau-Fischer, B., Cerf-Bensussan, N., Brousse, N., Cellier, C. & Hermine, O. 2010. Enteropathy-associated T-cell lymphoma: a review on clinical presentation, diagnosis, therapeutic strategies and perspectives. *Gastroenterol Clin* 

Adami, H. O. 2005. Family history of hematopoietic malignancy and risk of

Incidence and Risk Factors for Lymphoma in a Single-Center Inflammatory Bowel

Crohn's disease. Report of a case]. *Radiol Med,* 94, 122-4. Cancer-Research-UK. 2011. *Cancer Research UK* [Online]. Available:

treatment with infliximab. *Ann N Y Acad Sci,* 1107, 346-55.

lymphoma. *J Natl Cancer Inst,* 97, 1466-74.

Disease Population. *Dig Dis Sci*.

and NHS region. *The Stationary Office*.

for Crohn's disease. *N Engl J Med,* 362, 1383-95.

need for intestinal surgery. *Gut,* 54, 237-41.

bowel disease. *Lancet,* 343, 1249-52.

*Biomarkers Prev,* 15, 2078-85.

*Rev Immunol,* 8, 458-66.

*Gastroenterology,* 126, 19-31.

http://www.cancerresearchuk.org/.

*Biol,* 34, 590-605.

Nordic countries in relation to fallout from atmospheric nuclear weapons testing. *BMJ,* 304, 1005-9.


Evaluating Lymphoma Risk in Inflammatory Bowel Disease 347

Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F.,

Hanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., Macintosh, D.,

Hemminki, K., Li, X., Sundquist, J. & Sundquist, K. 2008. Cancer risks in ulcerative colitis

Hill, D. H., Mills, J. O. & Maxwell, R. J. 1993. Metachronous colonic lymphomas

Hjalgrim, H., Askling, J., Sorensen, P., Madsen, M., Rosdahl, N., Storm, H. H., Hamilton-

Holubar, S. D., Dozois, E. J., Loftus, E. V., Jr., Teh, S. H., Benavente, L. A., Harmsen, W. S.,

Hope-Ross, M., Magee, D. J., O'donoghue, D. P. & Murphy, J. J. 1985. Ulcerative colitis

Hurlstone, D. P. 2002. Early phase mantle cell lymphoma: macroscopic similarities to

Isomoto, H., Furusu, H., Onizuka, Y., Kawaguchi, Y., Mizuta, Y., Maeda, T. & Kohno, S.

Jaeger, G., Bauer, F., Brezinschek, R., Beham-Schmid, C., Mannhalter, C. & Neumeister, P.

Jaffe, E., Harris, N., Stein, H. & Vardiman, J. (eds.) 2001. *World Health Organisation* 

Jarnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlen, P., Granno, C., Vilien, M.,

Jess, T., Loftus, E. V., Jr., Velayos, F. S., Harmsen, W. S., Zinsmeister, A. R., Smyrk, T. C.,

study from olmsted county, Minnesota. *Gastroenterology,* 130, 1039-46.

combination of alemtuzumab and cladribine. *Ann Oncol,* 19, 1025-6.

complicated by lymphoma and adenocarcinoma. *Br J Surg,* 72, 22.

terminal ileal Crohn's disease. *Am J Gastroenterol,* 97, 1577-8.

complicating chronic ulcerative colitis. *Abdom Imaging,* 18, 369-70.

*Gastroenterology,* 130, 323-33; quiz 591.

prebiologic therapy era. *Inflamm Bowel Dis*.

ulcerative colitis. *Gastrointest Endosc,* 58, 805-8.

*Lymphoid Tissues*: IARC Press, Lyon.

lymphoma. *Ann Oncol,* 7 Suppl 4, 5-10.

patients. *Int J Cancer,* 123, 1417-21.

*Inst,* 92, 1522-8.

Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W. & Rutgeerts, P. 2002. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet,* 359, 1541-9.

Panaccione, R., Wolf, D. & Pollack, P. 2006. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Dutoit, S., Eriksen, L. S., Frisch, M., Ekbom, A. & Melbye, M. 2000. Risk of Hodgkin's disease and other cancers after infectious mononucleosis. *J Natl Cancer* 

Wolff, B. G., Cima, R. R. & Larson, D. W. 2010. Primary intestinal lymphoma in patients with inflammatory bowel disease: A descriptive series from the

2003. Colonic involvement by adult T-cell leukemia/lymphoma mimicking

2008. Hepatosplenic gammadelta T-cell lymphoma successfully treated with a

*Classification of Tumours. Pathology and Genetics of Tumours of Haemopoietic and* 

Strom, M., Danielsson, A., Verbaan, H., Hellstrom, P. M., Magnuson, A. & Curman, B. 2005. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. *Gastroenterology,* 128, 1805-11. Jarrett, A. F., Armstrong, A. A. & Alexander, E. 1996. Epidemiology of EBV and Hodgkin's

Schleck, C. D., Tremaine, W. J., Melton, L. J., 3rd, Munkholm, P. & Sandborn, W. J. 2006. Risk of intestinal cancer in inflammatory bowel disease: a population-based

W. 2000. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. *N Engl J Med,* 342, 1627-32.


Federman, J., Goldstein, M. E. & Weingarten, B. 1963. Malignant lymphoma of over fifteen

Fraser, A. G., Orchard, T. R. & Jewell, D. P. 2002. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. *Gut,* 50, 485-9. Friedman, H. B., Silver, G. M. & Brown, C. H. 1968. Lymphoma of the colon simulating

Frizzi, J. D., Rivera, D. E., Harris, J. A. & Hamill, R. L. 2000. Lymphoma arising in an S-

Froilan Torres, C., Castro Carbajo, P., Pajares Villarroya, R., Plaza Santos, R., Gomez Senent,

Funch, D. P., Walker, A. M., Schneider, G., Ziyadeh, N. J. & Pescovitz, M. D. 2005.

Gaulard, P., Bourquelot, P., Kanavaros, P., Haioun, C., Le Couedic, J. P., Divine, M.,

Ghosh, S. & Mitchell, R. 2007. Impact of inflammatory bowel disease on quality of life:

Glaser, S. L. 1991. Black-white differences in Hodgkin's disease incidence in the United States by age, sex, histology subtype and time. *Int J Epidemiol,* 20, 68-75. Goldin, L. R., Pfeiffer, R. M., Gridley, G., Gail, M. H., Li, X., Mellemkjaer, L., Olsen, J. H.,

Greenstein, A. J., Gennuso, R., Sachar, D. B., Heimann, T., Smith, H., Janowitz, H. D. &

Grulich, A. E., Vajdic, C. M. & Cozen, W. 2007a. Altered immunity as a risk factor for non-

Grulich, A. E., Van Leeuwen, M. T., Falster, M. O. & Vajdic, C. M. 2007b. Incidence of

Hodgkin lymphoma. *Cancer Epidemiol Biomarkers Prev,* 16, 405-8.

(EFCCA) patient survey. *J Crohns Colitis,* 1, 10-20.

recipients: a meta-analysis. *Lancet,* 370, 59-67.

related tumors. *Cancer,* 100, 1902-8.

ulcerative colitis. Report of four cases. *Am J Dig Dis,* 13, 910-7.

*N Engl J Med,* 342, 1627-32.

*Nucl Med,* 89, 771-8.

*Rectum,* 43, 540-3.

101, 288-94.

*Surgeons,* 5, 2894-900.

*Pathol,* 137, 617-28.

*Cancer,* 56, 2914-21.

W. 2000. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

years' duration masquerading as ulcerative colitis. *Am J Roentgenol Radium Ther* 

pouch after total proctocolectomy for ulcerative colitis: report of a case. *Dis Colon* 

S., Martin Arranz, M. D., Adan Merino, L., Martin Arranz, E., Mancenido Marcos, N., Peces, R. & Benito Lopez, D. 2009. Acute spontaneous tumor lysis syndrome in a patient with Crohn's disease taking immunosuppressants. *Rev Esp Enferm Dig,*

Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant* 

Goossens, M., Zafrani, E. S., Farcet, J. P. & Reyes, F. 1990. Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. *Am J* 

Results of the European Federation of Crohn's and Ulcerative Colitis Associations

Hemminki, K. & Linet, M. S. 2004. Familial aggregation of Hodgkin lymphoma and

Aufses, A. H., JR. 1985. Extraintestinal cancers in inflammatory bowel disease.

cancers in people with HIV/AIDS compared with immunosuppressed transplant


Evaluating Lymphoma Risk in Inflammatory Bowel Disease 349

Kuppers, R., Klein, U., Hansmann, M. L. & Rajewsky, K. 1999. Cellular origin of human B-

Lal, S. & Steinhart, A. H. 2006. Antibiotic therapy for Crohn's disease: a review. *Can J* 

Langmead, L. & Rampton, D. S. 2006. Review article: complementary and alternative therapies for inflammatory bowel disease. *Aliment Pharmacol Ther,* 23, 341-9. Larsson, S. C. & Wolk, A. 2007. Obesity and risk of non-Hodgkin's lymphoma: a meta-

Lemann, M., Mary, J. Y., Colombel, J. F., Duclos, B., Soule, J. C., Lerebours, E., Modigliani, R.

Lemann, M., Mary, J. Y., Duclos, B., Veyrac, M., Dupas, J. L., Delchier, J. C., Laharie, D.,

Leslie, W. D., Miller, N., Rogala, L. & Bernstein, C. N. 2008. Vitamin D status and bone

Lewis, J. D., Bilker, W. B., Brensinger, C., Deren, J. J., Vaughn, D. J. & Strom, B. L. 2001.

Lewis, J. D., Schwartz, J. S. & Lichtenstein, G. R. 2000. Azathioprine for maintenance of

Lichtenstein, G. R., Feagan, B. G., Cohen, R. D., Salzberg, B. A., Diamond, R. H., Chen, D. M.,

Ling, Y. H., Chan, J. Y., Beattie, K. L. & Nelson, J. A. 1992. Consequences of 6-thioguanine

Ljung, T., Karlen, P., Schmidt, D., Hellstrom, P. M., Lapidus, A., Janczewska, I., Sjoqvist, U.

Lofstrom, B., Backlin, C., Sundstrom, C., Ekbom, A. & Lundberg, I. E. 2007. A closer look at

Long, M. D., Herfarth, H. H., Pipkin, C. A., Porter, C. Q., Sandler, R. S. & Kappelman, M. D.

population based cohort from Stockholm County. *Gut,* 53, 849-53.

bowel disease. *Clin Gastroenterol Hepatol,* 8, 268-74.

randomized placebo-controlled trial. *Gastroenterology,* 130, 1054-61.

& Bouhnik, Y. 2005. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. *Gastroenterology,*

Moreau, J., Cadiot, G., Picon, L., Bourreille, A., Sobahni, I. & Colombel, J. F. 2006. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a

density in recently diagnosed inflammatory bowel disease: the Manitoba IBD

Inflammatory bowel disease is not associated with an increased risk of lymphoma.

remission in Crohn's disease: benefits outweigh the risk of lymphoma.

Pritchard, M. L. & Sandborn, W. J. 2006. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. *Clin Gastroenterol* 

incorporation into DNA on polymerase, ligase, and endonuclease reactions. *Mol* 

& Lofberg, R. 2004. Infliximab in inflammatory bowel disease: clinical outcome in a

non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. *Ann Rheum Dis,* 66, 1627-32. Loftus, E. V., Jr., Tremaine, W. J., Habermann, T. M., Harmsen, W. S., Zinsmeister, A. R. &

Sandborn, W. J. 2000. Risk of lymphoma in inflammatory bowel disease. *Am J* 

2010. Increased risk for non-melanoma skin cancer in patients with inflammatory

cell lymphomas. *N Engl J Med,* 341, 1520-9.

Cohort Study. *Am J Gastroenterol,* 103, 1451-9.

*Gastroenterology,* 121, 1080-7.

*Gastroenterology,* 118, 1018-24.

*Hepatol,* 4, 621-30.

*Pharmacol,* 42, 802-7.

*Gastroenterol,* 95, 2308-12.

analysis. *Int J Cancer,* 121, 1564-70.

*Gastroenterol,* 20, 651-5.

128, 1812-8.


Jess, T., Winther, K. V., Munkholm, P., Langholz, E. & Binder, V. 2004. Intestinal and extra-

Johnson, F. R., Hauber, B., Ozdemir, S., Siegel, C. A., Hass, S. & Sands, B. E. 2010. Are

preferences in Crohn's disease management. *J Manag Care Pharm,* 16, 616-28. Jost, P. J. & Ruland, J. 2007. Aberrant NF-kappaB signaling in lymphoma: mechanisms,

Jouini, S., Ayadi, K., Mokrani, A., Wachuku, E., Hmouda, H. & Gourdie, R. 2001. [Mediterranean lymphoma mimicking Crohn's disease]. *J Radiol,* 82, 855-8. Kandiel, A., Fraser, A. G., Korelitz, B. I., Brensinger, C. & Lewis, J. D. 2005. Increased risk of

Kang, H. Y., Hwang, J. H., Park, Y. S., Bang, S. M., Lee, J. S., Chung, J. H. & Kim, H. 2007.

Karlen, P., Lofberg, R., Brostrom, O., Leijonmarck, C. E., Hellers, G. & Persson, P. G. 1999.

Kashi, M. R., Belayev, L. & Parker, A. 2010. Primary extranodal Hodgkin lymphoma of the

Kastner, F., Paulus, W., Deckert, M., Schlegel, P., Evers, S. & Husstedt, I. W. 2007. [Primary

Kawashima, K., Hayashi, K., Ohnoshi, T., Teramoto, N. & Kimura, I. 1994. Epstein-Barr

Kelly, J. L., Friedberg, J. W., Calvi, L. M., Van Wijngaarden, E. & Fisher, S. G. 2009. Vitamin D and non-Hodgkin lymphoma risk in adults: a review. *Cancer Invest,* 27, 942-51. Kinney, T., Rawlins, M., Kozarek, R., France, R. & Patterson, D. 2003. Immunomodulators

Kotlyar, D. S., Blonski, W., Diamond, R. H., Wasik, M. & Lichtenstein, G. R. 2010.

Kroeker, K. I., Lam, S., Birchall, I. & Fedorak, R. N. 2011. Patients with IBD are exposed to

inflammatory bowel disease. *Clin Gastroenterol Hepatol,* 9, 36-41 e1.

characterization of a new cell line. *Jpn J Cancer Res,* 85, 1080-6.

Copenhagen County, Denmark. *Aliment Pharmacol Ther,* 19, 287-93.

consequences, and therapeutic implications. *Blood,* 109, 2700-7.

and 6-mercaptopurine. *Gut,* 54, 1121-5.

literature and case report]. *Nervenarzt,* 78, 451-6.

with 400 infusions. *Am J Gastroenterol,* 98, 608-12.

study. *J Clin Gastroenterol,* 45, 34-9.

*Gastroenterol,* 94, 1047-52.

2743-7.

8, A20.

intestinal cancer in Crohn's disease: follow-up of a population-based cohort in

gastroenterologists less tolerant of treatment risks than patients? Benefit-risk

lymphoma among inflammatory bowel disease patients treated with azathioprine

Angioimmunoblastic T-cell lymphoma mimicking Crohn's disease. *Dig Dis Sci,* 52,

Increased risk of cancer in ulcerative colitis: a population-based cohort study. *Am J* 

colon masquerading as new diagnosis of Crohn's disease. *Clin Gastroenterol Hepatol,*

CNS lymphoma in azathioprine therapy for autoimmune diseases: review of the

virus-associated post-transplant non-Hodgkin's lymphoma: establishment and

and "on demand" therapy with infliximab in Crohn's disease: clinical experience

Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. *Am J Gastroenterol,* 105, 2299-301. Kotlyar, D. S., Osterman, M. T., Diamond, R. H., Porter, D., Blonski, W. C., Wasik, M.,

Sampat, S., Mendizabal, M., Lin, M. V. & Lichtenstein, G. R. 2011. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with

high levels of ionizing radiation through CT scan diagnostic imaging: a five-year


Evaluating Lymphoma Risk in Inflammatory Bowel Disease 351

Newton, R., Ferlay, J., Beral, V. & Devesa, S. S. 1997. The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites. *Int J Cancer,* 72, 923-30. Nguyen, T., Vacek, P. M., O'neill, P., Colletti, R. B. & Finette, B. A. 2009. Mutagenicity and

Nishigami, T., Kataoka, T. R., Torii, I., Sato, A., Tamura, K., Hirano, H., Hida, N., Ikeuchi, H.

Nyam, D. C., Pemberton, J. H., Sandborn, W. J. & Savcenko, M. 1997. Lymphoma of the

O'donovan, P., Perrett, C. M., Zhang, X., Montaner, B., Xu, Y. Z., Harwood, C. A., Mcgregor,

Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H.,

Owen, C. E., Callen, J. P. & Bahrami, S. 2010. Cutaneous Lymphoproliferative Disorder

Packey, C. D. & Sartor, R. B. 2008. Interplay of commensal and pathogenic bacteria, genetic

Palli, D., Trallori, G., Bagnoli, S., Saieva, C., Tarantino, O., Ceroti, M., D'albasio, G., Pacini,

Panaccione, R., Colombel, J. F., Sandborn, W. J., Rutgeerts, P., D'haens, G. R., Robinson, A.

Parasher, G., Jaswal, S., Golbey, S., Grinberg, M. & Iswara, K. 1999. Extraintestinal non-

Parkin, D. M. 2006. The global health burden of infection-associated cancers in the year 2002.

Parnes, I. H., Warner, R. R., Berman, R. & Sanders, M. 1974. Diffuse lymphosarcoma of the

colon simulating ulcerative colitis. *Mt Sinai J Med,* 41, 802-6.

generate mutagenic oxidative DNA damage. *Science,* 309, 1871-4.

bowel disease. *Cancer Res,* 69, 7004-12.

*Pathol Res Pract,* 206, 846-50.

*Gastroenterol,* 21, 168-71.

bowel diseases. *J Intern Med,* 263, 597-606.

*Aliment Pharmacol Ther,* 31, 1296-309.

disease. *Am J Gastroenterol,* 94, 226-8.

*Int J Cancer,* 118, 3030-44.

with ulcerative colitis. *Gastroenterology,* 119, 647-53.

*Dermatol*.

971-2.

potential carcinogenicity of thiopurine treatment in patients with inflammatory

& Tsujimura, T. 2010. Concomitant adenocarcinoma and colonic non-Hodgkin's lymphoma in a patient with ulcerative colitis: a case report and molecular analysis.

pouch after ileal pouch-anal anastomosis: report of a case. *Dis Colon Rectum,* 40,

J. M., Walker, S. L., Hanaoka, F. & Karran, P. 2005. Azathioprine and UVA light

Moran, T., Karaliuskas, R., Duerr, R. H., Achkar, J. P., Brant, S. R., Bayless, T. M., Kirschner, B. S., Hanauer, S. B., Nunez, G. & Cho, J. H. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature,* 411, 603-6. Oruc, N., Ozutemiz, O., Tekin, F., Sezak, M., Tuncyurek, M., Krasinskas, A. M. &

Tombuloglu, M. 2010. Celiac disease associated with B-cell lymphoma. *Turk J* 

Complicating Infectious Mononucleosis in an Immunosuppressed Patient. *Pediatr* 

mutations, and immunoregulatory defects in the pathogenesis of inflammatory

F., Amorosi, A. & Masala, G. 2000. Hodgkin's disease risk is increased in patients

M., Chao, J., Mulani, P. M. & Pollack, P. F. 2010. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.

Hodgkin's lymphoma presenting as obstructive jaundice in a patient with Crohn's


Luo, J. C., Hwang, S. J., Li, C. P., Liu, J. H., Chen, P. M., Liu, S. M., Chiang, J. H., Chang, F. Y.

Luther, J., Dave, M., Higgins, P. D. & Kao, J. Y. 2010. Association between Helicobacter

Maaravi, Y., Wengrower, D. & Leibowitz, G. 1993. A unique presentation of lymphoma of

Mack, T. M., Cozen, W., Shibata, D. K., Weiss, L. M., Nathwani, B. N., Hernandez, A. M.,

Mariette, X., Cazals-Hatem, D., Warszawki, J., Liote, F., Balandraud, N. & Sibilia, J. 2002.

Martinez Tirado, P., Redondo Cerezo, E., Gonzalez Aranda, Y., M, J. C. T., Nogueras Lopez,

Mccullough, J. E., Kim, C. H. & Banks, P. M. 1992. Mantle zone lymphoma of the colon

Merhi, M., Raynal, H., Cahuzac, E., Vinson, F., Cravedi, J. P. & Gamet-Payrastre, L. 2007.

Miligi, L., Costantini, A. S., Benvenuti, A., Kriebel, D., Bolejack, V., Tumino, R., Ramazzotti,

Myerson, P., Myerson, D., Miller, D., Deluca, V. A., Jr. & Lawson, J. P. 1974.

Neri, A., Barriga, F., Inghirami, G., Knowles, D. M., Neequaye, J., Magrath, I. T. & Dalla-

Newnham, E., Hawkes, E., Surender, A., James, S. L., Gearry, R. & Gibson, P. R. 2007.

analysis of case-control studies. *Cancer Causes Control,* 18, 1209-26. MHRA. 2011. *MHRA* [Online]. Available: http://www.mhra.gov.uk/index.htm.

review of the literature. *Inflamm Bowel Dis,* 16, 1077-84.

young-adult form of the disease. *N Engl J Med,* 332, 413-8.

prospective study in France. *Blood,* 99, 3909-15.

bowel disease. *Ann Pharmacother,* 41, 21-8.

*Epidemiology,* 17, 552-61.

*Dis Colon Rectum,* 17, 710-5.

*Ther,* 26, 1019-24.

establishing the diagnosis. *Dig Dis Sci,* 37, 934-8.

the colon. *J Clin Gastroenterol,* 17, 49-51.

71.

& Lee, S. D. 1997. Primary low grade B-cell lymphoma of colon mimicking inflammatory bowel disease: a case report. *Zhonghua Yi Xue Za Zhi (Taipei),* 59, 367-

pylori infection and inflammatory bowel disease: a meta-analysis and systematic

Taylor, C. R., Hamilton, A. S., Deapen, D. M. & Rappaport, E. B. 1995. Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the

Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year

F. & Gomez Garcia, M. 2001. [Ki-1 lymphoma of the skin in a patient with Crohn's disease undergoing treatment with azathioprine]. *Gastroenterol Hepatol,* 24, 271-2. Masunaga, Y., Ohno, K., Ogawa, R., Hashiguchi, M., Echizen, H. & Ogata, H. 2007. Meta-

analysis of risk of malignancy with immunosuppressive drugs in inflammatory

simulating diffuse inflammatory bowel disease. Role of immunohistochemistry in

Occupational exposure to pesticides and risk of hematopoietic cancers: meta-

V., Rodella, S., Stagnaro, E., Crosignani, P., Amadori, D., Mirabelli, D., Sommani, L., Belletti, I., Troschel, L., Romeo, L., Miceli, G., Tozzi, G. A., Mendico, I. & Vineis, P. 2006. Occupational exposure to solvents and the risk of lymphomas.

Lymphosarcoma of the bowel masquerading as ulcerative colitis: report of a case.

Favera, R. 1991. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. *Blood,* 77, 1092-5.

Quantifying exposure to diagnostic medical radiation in patients with inflammatory bowel disease: are we contributing to malignancy? *Aliment Pharmacol* 


Evaluating Lymphoma Risk in Inflammatory Bowel Disease 353

Rutter, M. D., Saunders, B. P., Wilkinson, K. H., Rumbles, S., Schofield, G., Kamm, M. A.,

Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D.,

Sandborn, W. J., Hanauer, S. B., Rutgeerts, P., Fedorak, R. N., Lukas, M., Macintosh, D. G.,

Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N.,

Sartor, R. B. 2008. Microbial influences in inflammatory bowel diseases. *Gastroenterology,*

Satsangi, J., Silverberg, M. S., Vermeire, S. & Colombel, J. F. 2006. The Montreal classification

Schroder, O., Blumenstein, I. & Stein, J. 2006. Combining infliximab with methotrexate for

Schroder, O., Blumenstein, I., Schulte-Bockholt, A. & Stein, J. 2004. Combining infliximab

Schwartz, G. G. & Skinner, H. G. 2007. Vitamin D status and cancer: new insights. *Curr Opin* 

Schwartz, L. K., Kim, M. K., Coleman, M., Lichtiger, S., Chadburn, A. & Scherl, E. 2006. Case

Scully, C., Eveson, J. W., Witherow, H., Young, A. H., Tan, R. S. & Gilby, E. D. 1993. Oral

Sengul, N., Berho, M., Baig, M. K. & Weiss, E. 2008. Ileal pouch lymphoma following restorative proctocolectomy for ulcerative colitis. *Inflamm Bowel Dis,* 14, 584. Serraino, D., Salamina, G., Franceschi, S., Dubois, D., La Vecchia, C., Brunet, J. B. & Ancelle-

in the World Health Organization European Region. *Br J Cancer,* 66, 912-6.

controlled pilot study. *Eur J Gastroenterol Hepatol,* 18, 11-6.

azathioprine. *Aliment Pharmacol Ther,* 19, 295-301.

*Gastroenterology,* 130, 1030-8.

II trial. *Gut,* 56, 1232-9.

134, 577-94.

749-53.

disease. *N Engl J Med,* 350, 876-85.

*Clin Nutr Metab Care,* 10, 6-11.

University Hospital. *Digestion,* 70, 3-9.

*Hepatol,* 4, 1030-4.

Crohn's disease. *N Engl J Med,* 357, 228-38.

Williams, C. B., Price, A. B., Talbot, I. C. & Forbes, A. 2006. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis.

Bloomfield, R. & Schreiber, S. 2007a. Certolizumab pegol for the treatment of

Panaccione, R., Wolf, D., Kent, J. D., Bittle, B., Li, J. & Pollack, P. F. 2007b. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC

Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., Rachmilewitz, D., Rutgeerts, P., Wild, G., Wolf, D. C., Marsters, P. A., Travers, S. B., Blank, M. A. & Van Deventer, S. J. 2004. Infliximab maintenance therapy for fistulizing Crohn's

of inflammatory bowel disease: controversies, consensus, and implications. *Gut,* 55,

the induction and maintenance of remission in refractory Crohn's disease: a

and methotrexate in fistulizing Crohn's disease resistant or intolerant to

report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. *Clin Gastroenterol* 

presentation of lymphoma: case report of T-cell lymphoma masquerading as oral Crohn's disease, and review of the literature. *Eur J Cancer B Oral Oncol,* 29B, 225-9. Seiderer, J., Goke, B. & Ochsenkuhn, T. 2004. Safety aspects of infliximab in inflammatory

bowel disease patients. A retrospective cohort study in 100 patients of a German

Park, R. A. 1992. The epidemiology of AIDS-associated non-Hodgkin's lymphoma


Persson, P. G., Karlen, P., Bernell, O., Leijonmarck, C. E., Brostrom, O., Ahlbom, A. &

Peyrin-Biroulet, L., Laclotte, C. & Bigard, M. A. 2007. Adalimumab maintenance therapy for

Piccin, A., Cortelazzo, S., Rovigatti, U., Bourke, B. & Smith, O. P. 2010. Immunosuppressive

Pohl, C., Eidt, S., Ziegenhagen, D. & Kruis, W. 1991. [Immunoproliferative disease of the

Raderer, M., Puspok, A., Birkner, T., Streubel, B. & Chott, A. 2004. Primary gastric mantle

Redmond, M., Quinn, J., Murphy, P., Patchett, S. & Leader, M. 2007. Plasmablastic

Reijasse, D., Le Pendeven, C., Cosnes, J., Dehee, A., Gendre, J. P., Nicolas, J. C. & Beaugerie,

Rodrigo, L., Perez-Pariente, J. M., Fuentes, D., Cadahia, V., Garcia-Carbonero, A., Nino, P.,

Roelandt, P. R., Maertens, J., Vandenberghe, P., Verslype, C., Roskams, T., Aerts, R., Nevens,

Rubin, G. P., Hungin, A. P., Chinn, D. J. & Dwarakanath, D. 2004. Quality of life in patients

Rubin, G. P., Hungin, A. P., Kelly, P. J. & Ling, J. 2000. Inflammatory bowel disease:

Rutgeerts, P., D'haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer,

Rutgeerts, P., Van Assche, G. & Vermeire, S. 2004. Optimizing anti-TNF treatment in

inflammatory bowel disease. *Gastroenterology,* 126, 1593-610.

Pranesh, N. 2002. Lymphoma in an ileostomy. *Postgrad Med J,* 78, 368-9.

after immunosuppressive therapy. *J Clin Pathol,* 60, 80-1.

immunosuppressive therapy. *Inflamm Bowel Dis,* 10, 85-90.

*Gastroenterology,* 107, 1675-9.

*Wochenschr,* 116, 1265-9.

*Lymphoma,* 45, 1459-62.

*Dig,* 96, 548-54; 554-8.

*Aliment Pharmacol Ther,* 19, 529-35.

*Pharmacol Ther,* 14, 1553-9.

*Gastroenterology,* 117, 761-9.

15, 686-92.

85, 634.

*Aliment Pharmacol Ther,* 25, 675-80.

Hellers, G. 1994. Crohn's disease and cancer: a population-based cohort study.

Crohn's disease with intolerance or lost response to infliximab: an open-label study.

treatments in Crohn's disease induce myelodysplasia and leukaemia. *Am J Hematol,*

small intestine. A rare differential diagnosis of Crohn's disease]. *Dtsch Med* 

cell lymphoma in a patient with long standing history of Crohn's disease. *Leuk* 

lymphoma presenting as a paravertebral mass in a patient with Crohn's disease

L. 2004. Epstein-Barr virus viral load in Crohn's disease: effect of

De Francisco, R., Tojo, R., Moreno, M. & Gonzalez-Ballina, E. 2004. Retreatment and maintenance therapy with infliximab in fistulizing Crohn's disease. *Rev Esp Enferm* 

F. & Dierickx, D. 2009. Hepatosplenic gammadelta T-cell lymphoma after liver transplantation: report of the first 2 cases and review of the literature. *Liver Transpl,*

with established inflammatory bowel disease: a UK general practice survey.

epidemiology and management in an English general practice population. *Aliment* 

L., Van Hogezand, R. A., Braakman, T., Dewoody, K. L., Schaible, T. F. & Van Deventer, S. J. 1999. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.


Evaluating Lymphoma Risk in Inflammatory Bowel Disease 355

Tey, S. K., Marlton, P. V., Hawley, C. M., Norris, D. & Gill, D. S. 2008. Post-transplant

Theander, E., Henriksson, G., Ljungberg, O., Mandl, T., Manthorpe, R. & Jacobsson, L. T.

Toruner, M., Loftus, E. V., Jr., Harmsen, W. S., Zinsmeister, A. R., Orenstein, R., Sandborn,

Travis, L. B., Curtis, R. E., Glimelius, B., Holowaty, E., Van Leeuwen, F. E., Lynch, C. F.,

Van Dieren, J. M., Kuipers, E. J., Samsom, J. N., Nieuwenhuis, E. E. & Van Der Woude, C. J.

Van Domselaar, M., Lopez San Roman, A., Bastos Oreiro, M. & Garrido Gomez, E. 2010.

Vincenzi, B., Finolezzi, E., Fossati, C., Verzi, A., Santini, D., Tonini, G., Arullani, A. &

Von Roon, A. C., Reese, G., Teare, J., Constantinides, V., Darzi, A. W. & Tekkis, P. P. 2007. The risk of cancer in patients with Crohn's disease. *Dis Colon Rectum,* 50, 839-55. Vos, A. C., Bakkal, N., Minnee, R. C., Casparie, M. K., De Jong, D. J., Dijkstra, G., Stokkers,

Wagonfeld, J. B., Baker, A. L., Reed, J. S., Platz, C. E. & Kirsner, J. B. 1976. Acute dilation of

Winnicki, M., Gariepy, G., Sauthier, P. G. & Funaro, D. 2009. Hodgkin lymphoma presenting

Winther, K. V., Jess, T., Langholz, E., Munkholm, P. & Binder, V. 2004. Long-term risk of

inflammatory bowel disease. *Leuk Lymphoma,* 42, 521-6.

bowel diseases: A Dutch nationwide study. *Inflamm Bowel Dis*.

the colon in malignant lymphoma. *Gastroenterology,* 70, 264-7.

patients with inflammatory bowel disease. *Gastroenterology,* 134, 929-36. Travis, L. B., Curtis, R. E., Boice, J. D., Jr., Hankey, B. F. & Fraumeni, J. F., JR. 1991. Second

cancers following non-Hodgkin's lymphoma. *Cancer,* 67, 2002-9.

*Am J Hematol,* 83, 330-3.

*Cancer,* 126, 992-1003.

IBD. *Inflamm Bowel Dis,* 12, 311-27.

*Gastroenterol Hepatol,* 33, 12-6.

*J Low Genit Tract Dis,* 13, 110-4.

County. *Clin Gastroenterol Hepatol,* 2, 1088-95.

85, 1932-7.

hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen.

2006. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. *Ann Rheum Dis,* 65, 796-803. Thompson, C. A., Habermann, T. M., Wang, A. H., Vierkant, R. A., Folsom, A. R., Ross, J. A.

& Cerhan, J. R. 2010. Antioxidant intake from fruits, vegetables and other sources and risk of non-Hodgkin's lymphoma: the Iowa Women's Health Study. *Int J* 

W. J., Colombel, J. F. & Egan, L. J. 2008. Risk factors for opportunistic infections in

Adami, J., Gospodarowicz, M., Wacholder, S., Inskip, P. & Et Al. 1993. Second cancers among long-term survivors of non-Hodgkin's lymphoma. *J Natl Cancer Inst,*

2006. Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of

[Lymphoproliferative disorders in an inflammatory bowel disease unit].

Avvisati, G. 2001. Unusual presentation of Hodgkin's disease mimicking

P., Van Bodegraven, A. A., Pierik, M., Van Der Woude, C. J., Oldenburg, B. & Hommes, D. W. 2010. Risk of malignant lymphoma in patients with inflammatory

as a vulvar mass in a patient with crohn disease: a case report and literature review.

cancer in ulcerative colitis: a population-based cohort study from Copenhagen


Shale, M., Kanfer, E., Panaccione, R. & Ghosh, S. 2008. Hepatosplenic T cell lymphoma in

Shepherd, N. A., Hall, P. A., Williams, G. T., Codling, B. W., Jones, E. L., Levison, D. A. &

Siegel, C. A., Marden, S. M., Persing, S. M., Larson, R. J. & Sands, B. E. 2009. Risk of

Silano, M., Volta, U., Vincenzi, A. D., Dessi, M. & Vincenzi, M. D. 2008. Effect of a gluten-

Sivarajasingham, N., Adams, S. A., Smith, M. E. & Hosie, K. B. 2003. Perianal Hodgkin's lymphoma complicating Crohn's disease. *Int J Colorectal Dis,* 18, 174-6. Smedby, K. E., Hjalgrim, H., Askling, J., Chang, E. T., Gregersen, H., Porwit-Macdonald, A.,

Smith, M. A., Irving, P. M., Marinaki, A. M. & Sanderson, J. D. 2010. Review article:

Sokol, H. & Beaugerie, L. 2009. Inflammatory bowel disease and lymphoproliferative

Steinmaus, C., Smith, A. H., Jones, R. M. & Smith, M. T. 2008. Meta-analysis of benzene

Steurer, M., Stauder, R., Grunewald, K., Gunsilius, E., Duba, H. C., Gastl, G. & Dirnhofer, S.

Stevens, S. J., Verschuuren, E. A., Pronk, I., Van Der Bij, W., Harmsen, M. C., The, T. H.,

Swerdlow, S., Campo, E., Harris, N., Jaffe, E., Pileri, S., Stein, H., Thiele, J. & Vardiman, J.

Talbot, C., Sagar, P. M., Johnston, M. J., Finan, P. J. & Burke, D. 2005. Infliximab in the

Morson, B. C. 1989. Primary malignant lymphoma of the large intestine complicating chronic inflammatory bowel disease. *Histopathology,* 15, 325-37. Shimizu, Y., Kato, H. & Schull, W. J. 1990. Studies of the mortality of A-bomb survivors. 9.

Mortality, 1950-1985: Part 2. Cancer mortality based on the recently revised doses

lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

free diet on the risk of enteropathy-associated T-cell lymphoma in celiac disease.

Sundstrom, C., Akerman, M., Melbye, M., Glimelius, B. & Adami, H. O. 2006. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin

malignancy on thiopurine treatment with special reference to inflammatory bowel

exposure and non-Hodgkin lymphoma: biases could mask an important

2002. Hepatosplenic gammadelta-T-cell lymphoma with leukemic course after

Meijer, C. J., Van Den Brule, A. J. & Middeldorp, J. M. 2001. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. *Blood,*

(eds.) 2008. *World Health Organisation Classification of Tumours of the Haemopoietic and* 

surgical management of complex fistulating anal Crohn's disease. *Colorectal Dis,* 7,

inflammatory bowel disease. *Gut,* 57, 1639-41.

(DS86). *Radiat Res,* 121, 120-41.

*Clin Gastroenterol Hepatol,* 7, 874-81.

lymphoma by subtype. *J Natl Cancer Inst,* 98, 51-60.

disorders: the dust is starting to settle. *Gut,* 58, 1427-36.

disease. *Aliment Pharmacol Ther,* 32, 119-30.

association. *Occup Environ Med,* 65, 371-8.

renal transplantation. *Hum Pathol,* 33, 253-8.

*Lymphoid Tissues,* Lyon: IARC Press.

*Dig Dis Sci,* 53, 972-6.

97, 1165-71.

164-8.


**16** 

*Korea* 

**Development, Optimization and** 

**Oral Paclitaxel Formulation for** 

In-Hyun Lee, Jung Wan Hong, Yura Jang, Yeong Taek Park and Hesson Chung *Korea Institute of Science and Technology* 

*and Daehwa Pharmaceutical* 

**Single-Agent Anticancer Therapy** 

Paclitaxel, administered as intravenous infusion currently, is an effective anticancer drug belonging to the taxane family (Figure 1) and used in the treatment of a wide variety of cancers including breast and ovarian cancers (Rowinsky et al., 1995). Researchers have been looking for more effective and convenient ways to administer paclitaxel with less formulation-related toxicities than the commercially available formulations like Taxol® by Bristol-Meyers Squibb. It is well known that some of the limitations of the current formulation come from Cremophor EL, a polyoxyethylated castor oil. This particular component is known to cause hypersensitivity (Weiss et al., 1990), to be responsible for nonlinear pharmacokinetic behavior (Kearns et al., 1995; Gianni, 1995) and to cause paclitaxel precipitation oftentimes when diluted during the infusion process (Pfeifer, 1993). Formulations for paclitaxel and its analogs have been prepared in many different ways for various administration procedures (Kim et al., 2006; Xie et al., 2007; Sugahara et al., 2007; Singla et al., 2002; Hennenfent & Govindan, 2006). Several years ago, Abraxane®, a suspension of albumin nanoparticles containing paclitaxel, obtained approval to treat metastatic breast cancer patients (Ibrahim et al., 2002; Garber, 2004). Abraxane®, a solvent-

**1. Introduction** 

Fig. 1. Structure of paclitaxel

**Absorption Mechanism of DHP107,** 

